Roughly one in three American adults has fatty liver disease. There’s exactly one approved pill for the serious version of it. And the company behind that pill just answered one of the biggest questions hanging over the stock.
The market’s response? A slide.
Today we break down why that reaction looks like an opportunity.
Protect Purchasing Power (Sponsored)
When the U.S. left the gold standard in 1971, the rules of money changed almost overnight.
Today, with inflation concerns, heavy central-bank gold buying, and questions around the dollar, some investors are taking another look at physical gold for retirement diversification.
This free guide explains the history, the risks, and how eligible retirement funds may be used for gold without triggering an immediate taxable distribution.
See How Retirement Investors Are Adding Physical Gold Before the Next Big Shift
*Reagan Gold Group does not provide financial, legal, or tax advice. This information is for educational purposes only and should not be considered investment advice. All investments carry risk, including loss of principal. Past performance is not indicative of future results. Consult your licensed financial advisor before making investment decisions.
The Only Approved Drug for a Liver Epidemic Nobody Is Talking About
Madrigal Pharmaceuticals (NASDAQ: MDGL) recently traded around $477, which is more than 20% below its 52-week high. Nothing broke. The launch is working. New data just expanded the case for the drug. The stock fell anyway, and that’s the setup.
Here’s what you need to know: the company holds Rezdiffra, the first and only FDA-approved treatment for metabolic dysfunction-associated steatohepatitis.
MASH, if you want the shorthand. It’s a serious liver disease driven by fat buildup that can progress to cirrhosis and liver failure, and it affects tens of millions of Americans. Until Rezdiffra, there was no approved drug for it at all.
Secret System (Sponsored)
A Bloomberg Terminal costs about $32,000 a year.
But this stock rating system gives everyday investors powerful market intelligence for a fraction of that price.
According to The Wall Street Journal, it outperformed every firm reviewed.
Its “Buy” ratings have averaged a 303% gain, including winners and losers.
Get full access to the stock rating system here.
What Just Happened
The Data Drop The Stock Ignored
Madrigal Pharmaceuticals (NASDAQ: MDGL) published a secondary analysis of its Phase 3 trial in the Journal of Hepatology showing Rezdiffra produced consistent results across five major genetic risk variants tied to MASH.
The variants in question are behind the worst cases of the disease and were previously a legitimate open question: does the drug work across all of them, or just some?
The answer is all of them. That finding simplifies the prescribing picture for doctors considerably. You treat the disease, not the genotype. For a drug still in its commercial ramp, that kind of clarity matters more than it sounds.
The Commercial Engine Behind The Data
Before this publication, Rezdiffra was already scaling. Second-quarter sales came in at $364 million, up 71% from a year earlier. Over 49,000 patients were on the drug at the end of June, more than double the count twelve months prior.
Those are not numbers from a drug that’s struggling to find its footing.
The earnings date is November 4. That call is your next major checkpoint for prescription trajectory, payer dynamics, and any early signal on what the cirrhosis data setup looks like heading into next year.
Gold Keeps Climbing (Sponsored)
Gold has been one of 2026’s strongest major assets, and J.P. Morgan still sees room for more upside.
Its latest outlook puts gold near $6,000 by year-end, with forecasts reaching as high as $6,300.
For retirement savers still heavily exposed to stocks, that raises a simple question: how much gold belongs in the mix?
See How to Position Your Retirement Savings for Gold’s Next Move
*This is an advertisement.
If you no longer wish to receive promotional messages from this advertiser, please unsubscribe here. Or write to: 23901 Calabasas Road, Suite 2002, Calabasas, CA 91302
The First-Mover Advantage
No Competition With The Same Profile
Novo Nordisk’s Wegovy received its own MASH approval in August 2025, so the competitive narrative has been out there for a while.
What tends to get underplayed: MASH is a disease affecting tens of millions of people, and a GLP-1 like Wegovy and a liver-directed drug like Rezdiffra will almost certainly coexist, and likely combine.
Rezdiffra is a once-daily pill targeting the liver directly. It’s a different mechanism. Physicians who have been treating this patient population are increasingly comfortable with it.
First-mover advantage in specialty pharma is real, especially when the patient population is this large and diagnosis rates are still rising. You’re watching a drug move from launch curiosity to standard of care. That transition doesn’t reverse easily.
Prescription Momentum That’s Hard To Fake
The commercial launch has consistently outpaced early analyst expectations. Payer coverage has broadened. The sales force scaled without the stumbles that typically plague first-in-class drugs. Prescription counts have climbed every quarter since approval.
None of that gets reflected in a stock that’s sitting more than 20% off its high on sentiment-driven weakness. The gap between the business and the share price is why this name is in front of you today.
The Next Growth Layer: Cirrhosis
A Patient Population With Zero Approved Options
Rezdiffra is currently approved for non-cirrhotic MASH patients with moderate-to-advanced fibrosis. That’s already a large market. The next target is MASH cirrhosis, the more advanced stage where the liver has become severely scarred.
Madrigal estimates roughly 245,000 diagnosed patients sit in that category under specialist care, and there is currently no approved drug for any of them.
The Phase 3 outcomes trial is running now. Results are expected in 2027. If the data come through, Madrigal won’t have a MASH drug. It will have a MASH franchise.
Pipeline Optionality The Market Isn’t Paying For
Beyond the cirrhosis trial, Madrigal has more than ten MASH development programs running, including an oral GLP-1 candidate in Phase 1.
The longer-term thesis here is combination therapy: MASH is a complex metabolic disease, and the eventual standard of care will almost certainly pair a liver-directed agent with a weight-loss drug.
Rezdiffra is positioned as the backbone of any such combination. The market isn’t paying for that optionality right now. That’s the part worth sitting with.
One Number You Should Treat Carefully
The stock is down roughly 18% year-to-date and has slid nearly 10% over the past month. Both figures sound bad in isolation. Context matters.
Madrigal is still burning cash. Revenue is scaling fast, but the company isn’t profitable yet and doesn’t expect to turn the corner until next year. The balance sheet holds over $800 million in cash, which funds the current ramp without urgent dilution risk.
But you’re buying a growth story ahead of profitability, and that means the stock will be sensitive to any wobble in prescription trends or payer dynamics.
The year-to-date decline reflects biotech sector weakness and some rerating from the highs, not a fundamental break in the business.
Strip out the sector noise and what you have is a drug with accelerating adoption, a validated mechanism, and a data package that just got stronger. That’s the business you’re pricing.
Benjamin Graham's landmark book 'Security Analysis' (1934) was co-authored with which collaborator, giving the discipline its 'Graham and Dodd' name?
What Could Trip It Up
The cirrhosis trial is the biggest swing factor by far. If Maestro-NASH-Outcomes misses in 2027, a large portion of the forward revenue case disappears along with it. This is a binary catalyst. Size accordingly.
Single-product dependence is the other side of that coin. Madrigal’s entire commercial story runs through Rezdiffra. Any safety signal, coverage setback, or prescribing slowdown lands directly on the thesis with nothing to absorb the impact.
GLP-1 competition is real, even if it’s nuanced. Novo Nordisk is already in the market. Eli Lilly’s drugs could follow with strong data.
If the GLP-1 players crowd out the market more aggressively than expected, the combination therapy thesis still applies, but it takes longer to play out.
Payer pressure is the quieter risk. Specialty drugs at this price point face constant scrutiny from pharmacy benefit managers. Coverage has expanded, but it isn’t permanent, and any shift in reimbursement policy could slow the prescription ramp.
My Take
The market has handed you a first-mover drug in a massive underserved disease area, sitting more than 20% off its high, with a fresh data package, an accelerating commercial launch, and a cirrhosis catalyst on the horizon that no analyst has fully priced in.
Fair-value models peg this stock more than 40% above where it trades today.
The average analyst price target sits well above the current price. That gap doesn’t exist because the sell-side is wrong about the drug. It exists because the stock has drifted on sector weakness while the fundamentals kept moving in the right direction.
The thesis breaks if cirrhosis data fails or a safety issue emerges.
Set a mental stop around $420. If the stock breaks through that level on fundamental news, reassess before adding. Otherwise, the launch is working, the data is getting stronger, and the market hasn’t caught up.
Entry zone: $460 to $490. Add on weakness toward $440. Target: $625 to $680 over 9 to 15 months. Confidence: high.
Action Recap
Looking to buy? Start a position in the $460 to $490 range. The recent slide has given you a cleaner entry than you would have had a few months ago. November 4 earnings is your first major checkpoint.
Already own it? Hold through the current weakness. Watch the Q3 call for prescription trajectory and any early commentary on payer dynamics. Those are the two signals that move the thesis forward or back before the cirrhosis data arrives.
Main risk to respect: The cirrhosis trial is binary. If that data misses in 2027, the stock takes a serious hit. Keep your position at a size where you can absorb that scenario without making a forced decision.
That's our coverage for today; thanks for reading! Reply to this email with feedback or any value stocks you want me to check out.
Best Regards,
—Noah Zelvis
Undervalued Edge
